{"entity":{"id":"nct06610734","kind":"trial","name":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext","aka":["SKY"],"tldr":"A phase 2 trial of adebrelimab in lung cancer, run by Sichuan University, now recruiting.","summary":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) is a phase 2, randomised interventional study registered as NCT06610734 by Sichuan University, with a registry enrolment figure of 202 participants, started 2024-12-23 and due to reach its primary completion in 2026-12. Interventions recorded: Adebrelimab; Chemotherapy; low dose radiotherapy. Conditions listed: Small Cell Lung Cancer Extensive Stage. Primary outcome: overall survival. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed extensive small cell lung cancer (according to the VALG staging system);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06610734","url":"https://clinicaltrials.gov/study/NCT06610734"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06610734","phase":"2","setting":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)","sponsor":"Sichuan University","enrolled":202,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06610734/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}